文献速递前列腺癌前列腺增生与排尿功能障碍

前列腺癌幸存者尿失禁的经济负担:MEPS 2016-2021结果

Economic Burden of Urinary Incontinence in Men With Prostate Cancer: Results From the Medical Expenditure Panel Survey (2016-2021).
PubMed 文献 · Urology · 2025-09-12

基于2016-2021年医疗支出面板调查的横断面分析,纳入自报前列腺癌的男性并按尿失禁状态分组。调整年龄、种族、保险和教育后,尿失禁与高于平均总支出风险升高相关,主要由门诊就诊和门诊支出驱动;尿失禁组年均门诊就诊9次,无尿失禁组6次。

要点

  • 尿失禁与前列腺癌幸存者高于平均总医疗支出的风险升高相关(aOR 2.33)。
  • 门诊就诊频率更高(年均9次 vs 6次,P=.015),门诊支出风险亦升高。
  • 尿失禁组更常无保险(8.9% vs 1.1%)且较少拥有私人保险(2.5% vs 14.7%)。

核心结论

  • 尿失禁显著增加前列腺癌幸存者的医疗利用和支出,尤其通过门诊护理和失禁相关医疗用品。

研究设计与样本

  • 基于2016-2021年医疗支出面板调查的横断面分析,纳入自报前列腺癌的男性并按尿失禁状态分组。
  • 最终加权研究人群代表3,060,848名前列腺癌幸存者,其中76,759名伴尿失禁,2,984,089名不伴尿失禁。

主要发现

  • 伴尿失禁者更常无保险(8.9% vs 1.1%;P=.004),较少拥有私人保险(2.5% vs 14.7%;P=.004)。
  • 调整后,尿失禁与高于平均总支出风险升高相关(aOR 2.33;95%CI 1.18-4.60;P=.015)。
  • 门诊就诊风险升高(aOR 3.81;1.76-2.76;P=.001),门诊支出风险升高(aOR 2.46;95%CI 1.10-5.50;P=.029)。
  • 其他非设施相关支出风险升高(aOR 2.43;95%CI 1.17-5.08;P=.018)。
  • 伴尿失禁者年均门诊就诊9次,不伴尿失禁者6次(P=.015)。

临床怎么用

  • 对前列腺癌幸存者应主动评估和管理尿失禁,以减少门诊就诊和长期经济负担。
  • 关注失禁相关医疗用品支出,可能作为干预和费用控制的重点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the economic burden of urinary incontinence among prostate cancer survivors using nationally representative data, focusing on differences in healthcare expenditures and utilization between survivors with and without incontinence. METHODS: We conducted a cross-sectional analysis using 2016-2021 data from the Medicare Expenditure Panel Survey. Men with self-reported prostate cancer were categorized by incontinence status. The primary outcome was the likelihood of incurring above-average total healthcare expenditures. Secondary outcomes included expenditures by care setting and frequency of outpatient visits. Survey-weighted multivariable logistic regression models were utilized to analyze expenditures, adjusting for age, race, insurance status, and education level. RESULTS: The final weighted study population represented 3,060,848 prostate cancer survivors (76,759 with incontinence and 2,984,089 without). Survivors with incontinence were more often uninsured (8.9% vs 1.1%; P=.004) and less likely to have private insurance (2.5% vs 14.7%; P=.004). After adjustment, incontinence was associated with higher odds of above-average total expenditures (adjusted odds ratio [aOR] 2.33; 95% confidence interval [CI] 1.18-4.60; P=.015), largely driven by outpatient visits (aOR 3.81; 1.76-2.76; P=.001), outpatient expenditures (aOR 2.46; 95% CI 1.10-5.50; P=.029) and other non-facility-related expenditures (aOR 2.43; 95% CI 1.17-5.08; P=.018). Survivors with incontinence averaged 9 outpatient visits annually versus 6 among those without incontinence (P=.015). CONCLUSION: Urinary incontinence significantly increases healthcare utilization and expenditures among prostate cancer survivors, particularly through outpatient care and incontinence-related medical supplies. Targeted strategies to prevent and manage incontinence may reduce long-term economic burden and improve survivorship care.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Slota J, Naser-Tavakolian A, Ji E, et al. Economic Burden of Urinary Incontinence in Men With Prostate Cancer: Results From the Medical Expenditure Panel Survey (2016-2021). Urology. 2025. PMID: 40946921. doi:10.1016/j.urology.2025.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。